NTLA
Intellia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.14
−0.98%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.82
- Revenue estimate
- $10.0M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.80
- EPS estimate
- -$0.80
- Revenue actual
- $7.7M
- Revenue estimate
- $13.4M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- +9.5%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $20
- PT range
- $9.00 – $30
- Analysts
- 5
3 Buy1 Hold1 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.80 | -$0.80 | Miss -0.09% | $7.7M |
| May 11, 2026 | -$0.92 | -$0.81 | Beat 11.96% | $15.0M |
| Feb 26, 2026 | -$0.99 | -$0.83 | Beat 16.16% | $23.0M |
| Nov 6, 2025 | -$1.02 | -$0.92 | Beat 9.80% | $13.8M |
| Aug 7, 2025 | -$1.03 | -$0.99 | Beat 3.88% | $14.2M |
| May 8, 2025 | -$1.26 | -$1.10 | Beat 12.70% | $16.6M |
| Feb 27, 2025 | -$1.32 | -$1.24 | Beat 6.06% | $12.9M |
| Nov 7, 2024 | -$1.37 | -$1.34 | Beat 2.19% | $9.1M |
| Aug 8, 2024 | -$1.21 | -$1.31 | Miss -8.26% | $7.0M |
| May 9, 2024 | -$1.35 | -$1.06 | Beat 21.48% | $28.9M |
| Feb 22, 2024 | -$1.47 | -$1.46 | Beat 0.68% | $1.9M |
| Nov 9, 2023 | -$1.52 | -$1.38 | Beat 9.21% | $12.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026